RNA5SP343: A Potential Drug Target and Biomarker (G100873605)

Target Name: RNA5SP343

NCBI ID: G100873605

RNA5SP343

Other Name(s): RN5S343 | RNA, 5S ribosomal pseudogene 343

RNA5SP343: A Potential Drug Target and Biomarker

RNA5SP343 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and has been shown to play a role in a variety of cellular processes, including cell growth, apoptosis, and translation. RNA5SP343 is also known as KIAA1896 and has been shown to interact with several protein kinases, including AGO1 and p21.

The drug target potential of RNA5SP343 is due to its unique structure and the various functions it has been shown to play in the cell. RNA5SP343 is a small RNA molecule that is only 20 amino acids long. It has a unique 5'-end structure and a stem-loop region in the middle of the molecule. This stem-loop region is thought to play a key role in RNA5SP343's regulation of the cell cycle and has been shown to interact with several protein kinases.

RNA5SP343 has been shown to play a role in the regulation of the cell cycle. It is a negative regulator of the G1 phase and has been shown to interact with the protein kinase AGO1. AGO1 is a key regulator of the cell cycle and has been shown to play a role in the regulation of several cellular processes, including cell growth, apoptosis, and translation. RNA5SP343 has been shown to interact with AGO1 and to inhibit its activity. This interaction between RNA5SP343 and AGO1 suggests that RNA5SP343 may be a potential drug target for therapies that target the cell cycle.

RNA5SP343 has also been shown to play a role in the regulation of apoptosis. It is a regulator of the transition to apoptosis and has been shown to interact with the protein Bcl-2. Bcl-2 is a protein that has been shown to play a role in the regulation of apoptosis and has been shown to be a potential drug target for therapies that target apoptosis. RNA5SP343 has been shown to interact with Bcl-2 and to regulate its activity. This interaction between RNA5SP343 and Bcl-2 suggests that RNA5SP343 may be a potential biomarker for apoptosis and may be a target for therapies that target this process.

RNA5SP343 has also been shown to play a role in the regulation of translation. It is a regulator of the start of the translation process and has been shown to interact with the protein TRF-1. TRF-1 is a protein that has been shown to play a role in the regulation of translation and has been shown to be a potential drug target for therapies that target this process. RNA5SP343 has been shown to interact with TRF-1 and to regulate its activity. This interaction between RNA5SP343 and TRF-1 suggests that RNA5SP343 may be a potential drug target for therapies that target translation.

In conclusion, RNA5SP343 is a non-coding RNA molecule that has been shown to play a role in the regulation of the cell cycle, apoptosis, and translation. Its unique structure and interactions with protein kinases make it a potential drug target and biomarker. Further research is needed to fully understand the functions of RNA5SP343 and its potential as a drug target and biomarker.

Protein Name: RNA, 5S Ribosomal Pseudogene 343

The "RNA5SP343 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA5SP343 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets